CDE Opens Public Comment on 112th Draft Batch of Reference Preparations Catalogue for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 112th Draft Batch of Reference Preparations Catalogue for Chemical Generic Drugs

China's Center for Drug Evaluation (CDE), under the National Medical Products Administration (NMPA), released the draft for comment of the 112th Batch of the Catalogue of Reference Preparations for Chemical…

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
CompanyDrug

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis
CompanyDrug

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
CompanyDrug

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia
CompanyDrug

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Henlius and Organon's HLX11 Approved in Brazil – First Pertuzumab Biosimilar Cleared by Anvisa for HER2‑Positive Breast Cancer
CompanyDrug

Henlius and Organon’s HLX11 Approved in Brazil – First Pertuzumab Biosimilar Cleared by Anvisa for HER2‑Positive Breast Cancer

Novo Nordisk Wins CNIPA Patent Term Extension for Ozempic – CKD Indication Exclusivity in China Extended to March 2031
CompanyDrug

Novo Nordisk Wins CNIPA Patent Term Extension for Ozempic – CKD Indication Exclusivity in China Extended to March 2031

GenSci’s Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis

GenSci's Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the registration clinical trial application for GenSci117 inhalation powder, developed by its subsidiary Changchun Genescience Pharmaceutical Co., Ltd. ("GenSci"), has been accepted by China's National Medical Products Administration…

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania
CompanyDeals

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Visen Pharmaceuticals Designates Distinct HealthCare as Skytrofa Partner Institution at CIIE – Expanding Weekly Long‑Acting Growth Hormone Into China's Private Healthcare Channel
CompanyDeals

Visen Pharmaceuticals Designates Distinct HealthCare as Skytrofa Partner Institution at CIIE – Expanding Weekly Long‑Acting Growth Hormone Into China’s Private Healthcare Channel

JW Therapeutics Transfers Greater China and ASEAN Rights in Solid Tumor Cell Therapy Programs to Eureka – Deal Includes GPC3 and AFP‑Targeted TCR‑T Candidates
CompanyDeals

JW Therapeutics Transfers Greater China and ASEAN Rights in Solid Tumor Cell Therapy Programs to Eureka – Deal Includes GPC3 and AFP‑Targeted TCR‑T Candidates

RemeGen Licenses Global Rights to Rongchang's Pan‑RAS(ON) Inhibitor RCZY‑690 – Deal Value up to RMB 4.87 Billion
CompanyDeals

RemeGen Licenses Global Rights to Rongchang’s Pan‑RAS(ON) Inhibitor RCZY‑690 – Deal Value up to RMB 4.87 Billion

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML
CompanyDrug

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus
CompanyDeals

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

Hangzhou RonGu Biotechnology Co., Ltd. ("RonGu Biotechnology") announced the completion of a Series A financing of nearly RMB 100 million. The round was jointly participated by Changjin Holdings, Yichen Investment,…

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer's Disease Diagnosis and Treatment
CompanyDeals

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer’s Disease Diagnosis and Treatment

Sanyou Biopharmaceuticals Completes Series C Financing of Nearly RMB 100 Million – Zero2IPO Industry Investment Fund Backs AI‑Driven Drug Discovery Platform
CompanyDeals

Sanyou Biopharmaceuticals Completes Series C Financing of Nearly RMB 100 Million – Zero2IPO Industry Investment Fund Backs AI‑Driven Drug Discovery Platform

Boehringer Ingelheim and Ruijin Hospital Launch "China Bronchiectasis Care Action" at CIIE – Advancing Standardized Diagnosis and Long‑Term Disease Management
CompanyDeals

Boehringer Ingelheim and Ruijin Hospital Launch “China Bronchiectasis Care Action” at CIIE – Advancing Standardized Diagnosis and Long‑Term Disease Management

XtalPi Partners with Pierre Fabre Laboratories – AI‑Powered Drug Discovery Alliance Targeting Novel Oncology Therapies
CompanyDeals

XtalPi Partners with Pierre Fabre Laboratories – AI‑Powered Drug Discovery Alliance Targeting Novel Oncology Therapies

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…

China's NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape
Policy / Regulatory

China’s NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

China's National Joint Procurement Office Disqualifies Eugia Pharma and JSC "Farmak" Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules
Policy / Regulatory

China’s National Joint Procurement Office Disqualifies Eugia Pharma and JSC “Farmak” Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules

China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status
Policy / Regulatory

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

More News

WuXi AppTec Removed From DoD 1260H Chinese Military Companies List – Legal Challenge Ends Adverse Designation
Legal / IP

WuXi AppTec Removed From DoD 1260H Chinese Military Companies List – Legal Challenge Ends Adverse Designation

Viatris Reports Stable Q3 2026 Results with Enhanced Profitability – Raises Full‑Year Guidance as Pacira BioSciences Acquisition Nears Completion
Company

Viatris Reports Stable Q3 2026 Results with Enhanced Profitability – Raises Full‑Year Guidance as Pacira BioSciences Acquisition Nears Completion

Genoria and iCamuno Biotherapeutics Establish Joint Venture in Shanghai Free Trade Zone – Pioneering AI‑Driven Autologous Cell Therapy
CompanyDeals

Genoria and iCamuno Biotherapeutics Establish Joint Venture in Shanghai Free Trade Zone – Pioneering AI‑Driven Autologous Cell Therapy

Bayer Signs Strategic Agreements with ACITS and GHIC at CIIE – Building an Open Innovation Ecosystem in Urological Oncology
CompanyDeals

Bayer Signs Strategic Agreements with ACITS and GHIC at CIIE – Building an Open Innovation Ecosystem in Urological Oncology

Hangzhou Diagens Forges Strategic Partnership with Yongjiang Laboratory – Deploying Medical Imaging Large Models Across Guangxi and ASEAN
CompanyDeals

Hangzhou Diagens Forges Strategic Partnership with Yongjiang Laboratory – Deploying Medical Imaging Large Models Across Guangxi and ASEAN

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody
CompanyDeals

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program
CompanyDeals

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets
CompanyDeals

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Show More